is part of the Informa Markets Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
2020 has redefined disruption. But it has also brought out the collective spirit of the pharma industry as new partnerships were created, new ways of dealing with challenges were discovered.
Faced with the task of finding a vaccine for COVID-19, while keeping up the supply of lifesaving drugs with a severely strained supply chain, the pharma industry has shown incredible resilience.
After careful consideration and months of discussion with partners and key industry stakeholders, we have taken the difficult decision to postpone CPhI Japan until April 2021.
With international travel only returning gradually and different countries at various stages of recovery following the COVID-19 outbreak, it has become apparent that it would be difficult for us to guarantee the level of international participation and high-quality event experience that our community has come to expect of CPhI Japan.
In light of the recent novel coronavirus disease (COVID-19) developments, the organizer has taken the following preventive measures for the safety and well-being of exhibitors and visitors.
This report highlights trends in Japan’s pharma market, notably how costly, long-listed products will be replaced due to generic and biosimilar industries continuing to grow in volume and market share. It also discusses increased internationalisation of innovation, with a rise in acquisitions and partnerships with academia.
Our 2021 Pharma Outlook report has been published in collaboration with some of Pharma’s biggest names to provide key insights that will help you navigate the next 12 months and grow your business.
2020 has been one of the most turbulent years in recent history, casting a shroud of uncertainty over the pharma industry’s future.
Pharma’s response to the COVID-19 pandemic, in terms of vaccine development and treatment distribution, has grabbed many recent headlines, but the major challenges facing the pharma industry are by no means exclusively Coronavirus related.
In interviews with some of the industry’s experts, the 2021 Pharma Outlook report identifies major and emerging trends that will be prominent in 2021.